M. Kinzig‐Schippers

Author

M. Kinzig‐Schippers

Institute for Biomedical and Pharmaceutical Research

Also Known As

M KINZIGSCHIPPERS, M Kinzig-Schippers, M. KINZIG-SCHIPPERS, M. Kinzig-Schippers, M. Kinzig-schippers, M. Kinzig‐Schippers, Marion Kinzig-Schippers

Publications

440

Citations

H-Index

Concepts

All Affiliations

Institute for Biomedical and Pharmaceutical Research Albany Research Institute United States Army Medical Research Institute of Infectious Diseases University of Duisburg-Essen University of Cologne

About

M. Kinzig‐Schippers is an author at Institute for Biomedical and Pharmaceutical Research specializing in medicine, pharmacology, and clinical microbiology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	4	4	122
2	Health Sciences	3	3	101
3	Microbiology	2	2	56
4	Biostatistics	1	1	90
5	Orthopaedics	1	1	21

M. Kinzig‐Schippers

Publications

422

Citations

H-Index

Page 1

	Year	Citations
Systematic Comparison of the Population Pharmacokinetics and Pharmacodynamics of Piperacillin in Cystic Fibrosis Patients and Healthy Volunteers Jürgen B. Bulitta, Stephen B. Duffull, M. Kinzig‐Schippers, Antimicrobial Agents and Chemotherapy	2007	118
Development of a new G-CSF product based on biosimilarity assessment Pere Gascón, Uwe Fuhr, F. Sörgel, Annals of Oncology BioanalysisBiotechnologyBiostatisticsGenetically Modified OrganismNew G-csf Product	2009	90
Urinary bactericidal activity and pharmacokinetics of enoxacin versus norfloxacin and ciprofloxacin in healthy volunteers after a single oral dose Michaela Well, Kurt G. Naber, M. Kinzig‐Schippers, International Journal of Antimicrobial Agents UrologyAntimicrobial SusceptibilityHealth SciencesAntibioticsMedicine	1998	45
Kinetics of piperacillin and tazobactam in ventricular cerebrospinal fluid of hydrocephalic patients Roland Nau, M. Kinzig‐Schippers, F. Sörgel, Antimicrobial Agents and Chemotherapy	1997	43
Interaction of pefloxacin and enoxacin with the human cytochrome P450 enzyme CYP1A2 M. Kinzig‐Schippers, Uwe Fuhr, M Zaigler, Clinical Pharmacology & Therapeutics	1999	39
Use of an In Vitro Pharmacodynamic Model To Derive a Linezolid Regimen That Optimizes Bacterial Kill and Prevents Emergence of Resistance in <i>Bacillus anthracis</i> Arnold Louie, Henry S. Heine, Kiho Kim, Antimicrobial Agents and Chemotherapy Quantitative PharmacologyAntimicrobial ChemotherapyAntibiotic ResistanceBacterial PathogensPhysiologically-based Pharmacokinetic Modeling	2008	37
Concentrations of piperacillin–tazobactam in human jaw and hip bone Bilal Al‐Nawas, M. Kinzig‐Schippers, Fritz Söergel, Journal of Cranio-Maxillofacial Surgery Hip BoneMedicineBone MetabolismPharmacologyOsteoporosis	2008	21
Use of an <i>In</i> <i>Vitro</i> Pharmacodynamic Model To Derive a Moxifloxacin Regimen That Optimizes Kill of <i>Yersinia pestis</i> and Prevents Emergence of Resistance Arnold Louie, Henry S. Heine, Brian VanScoy, Antimicrobial Agents and Chemotherapy Microbial PathogensAntiparasitic AgentAntimicrobial ChemotherapyAntibiotic ResistanceBacterial Pathogens	2010	19
ABSORPTION OF INTRAVESICALLY APPLIED DRUGS: COMPARISON OF NORMAL AND ILEAL AUGMENTED RABBIT BLADDER S. Krege, M. Kinzig‐Schippers, F. Sörgel, The Journal of Urology	2004	10

Page 1